.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Queensland Health
UBS
McKesson
Chinese Patent Office
Express Scripts
McKinsey
Deloitte
Medtronic
Mallinckrodt

Generated: December 17, 2017

DrugPatentWatch Database Preview

NUVIGIL Drug Profile

« Back to Dashboard

When do Nuvigil patents expire, and what generic alternatives are available?

Nuvigil is a drug marketed by Cephalon and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in NUVIGIL is armodafinil. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the armodafinil profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
CephalonNUVIGILarmodafinilTABLET;ORAL021875-001Jun 15, 2007ABRXYesNo► Subscribe► SubscribeY► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-005Mar 26, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-002Mar 26, 2009DISCNYesNo► Subscribe► SubscribeY► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-005Mar 26, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-001Jun 15, 2007ABRXYesNo► Subscribe► SubscribeY► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-002Mar 26, 2009DISCNYesNo► Subscribe► SubscribeY► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-003Jun 15, 2007ABRXYesNo► Subscribe► SubscribeY► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-003Jun 15, 2007ABRXYesNo► Subscribe► SubscribeY► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-004Jun 15, 2007ABRXYesYes► Subscribe► SubscribeY► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-004Jun 15, 2007ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NUVIGIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
CephalonNUVIGILarmodafinilTABLET;ORAL021875-004Jun 15, 2007► Subscribe► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-001Jun 15, 2007► Subscribe► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-004Jun 15, 2007► Subscribe► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-005Mar 26, 2009► Subscribe► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-003Jun 15, 2007► Subscribe► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-002Mar 26, 2009► Subscribe► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-003Jun 15, 2007► Subscribe► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-002Mar 26, 2009► Subscribe► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-001Jun 15, 2007► Subscribe► Subscribe
CephalonNUVIGILarmodafinilTABLET;ORAL021875-005Mar 26, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for NUVIGIL

Drugname Dosage Strength RLD Submissiondate
armodafinilTablets50 mg, 150 mg and 250 mgNuvigil7/24/2009
armodafinilTablets100 mg and 200 mgNuvigil9/11/2009

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
UBS
Baxter
Chubb
Merck
Federal Trade Commission
Citi
Moodys
Medtronic
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot